Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!
oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]
AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.
- AstraZeneca-Dizal deal opens US access to sunvozertinib (3)
- Testing, treatment gaps and rising rare-NSCLC approvals (3)
- WU-KONG1B confirms sunvozertinib activity in EGFR Exon20 (3)
AstraZeneca-Dizal deal opens US access to sunvozertinib
Testing, treatment gaps and rising rare-NSCLC approvals
WU-KONG1B confirms sunvozertinib activity in EGFR Exon20
The RAS Inhibitor Daraxonrasib is Showing Encouraging New Results – Dana-Farber
oncodaily - Dana-Farber Cancer Institute shared a post on LinkedIn: “For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent. New […]
AI Summary: A targeted RAS inhibitor, daraxonrasib, produced promising clinical activity in patients with NRAS-mutant melanoma, demonstrating tumor responses and a tolerable safety profile in early studies. The data suggest a viable therapeutic avenue for a historically hard-to-treat subset and justify larger trials to confirm benefit — because apparently NRAS wasn’t going to cure itself.
New study sheds light on how Epstein-Barr virus may contribute to multiple sclerosis
medicalxpress - Multiple sclerosis (MS) is a chronic autoimmune disorder that attacks the central nervous system. For years, Epstein-Barr virus (EBV) has been strongly linked to MS, as nearly every person diagnosed with the condition shows evidence of past EBV infection.…
AI Summary: Researchers report that immune responses to Epstein‑Barr virus are implicated in multiple sclerosis, with EBV‑reactive CD4+ T cells enriched in people with MS. The work provides mechanistic evidence connecting prior infection to neuroinflammation and suggests antiviral or immune‑directed strategies might be viable prevention or treatment avenues — assuming we like attacking tiny viral culprits.
Stopping myeloma maintenance after two years shows no survival loss in trial
medicalxpress - For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment. A randomized phase 3…
AI Summary: Long‑term follow‑up from a randomized multiple myeloma maintenance study indicates that stopping lenalidomide after two years yields similar overall survival to continuing indefinitely. The data support a limited‑duration maintenance strategy that may spare patients toxicity and costs without sacrificing outcomes — revolutionary for weary patients and budget‑conscious oncologists alike.
- Clinicians and advocates react: praise and guidance after ENDURANCE results (6)
- ENDURANCE trial: Two-year lenalidomide equals continuous therapy (3)
Clinicians and advocates react: praise and guidance after ENDURANCE results
ENDURANCE trial: Two-year lenalidomide equals continuous therapy
St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia
oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]
AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.
Genetic study redefines a form of excessive sweating as a treatable neurological condition
medicalxpress - An international research team led by Dr. Frank Bosmans (Vrije Universiteit Brussel) has discovered a major genetic cause of hyperhidrosis (chronic and excessive sweating). The study, published in Science Advances, provides strong evidence that a genetica…
AI Summary: New research identifies a genetic basis and a tiny electrically gated ion channel in nerve cells as drivers of a form of excessive sweating, recasting it as a neurological condition rather than a benign nuisance. Findings point to potential targeted therapies that address the underlying neural mechanism rather than symptom management alone.